As TGF-β inhibitors are mainly targeting the tumor microenvironments with a minimal cytotoxicity, they should be used in combination with cytotoxic agents to kill the cancer cells and revert tumor favorable microenvironments. This evidence concerns the gene TGFB1 and cancer.